FDA told Ketacyn Pharmaceuticals to stop selling unapproved ketamine injection and ketamine gummies to U.S. consumers online.
What happened
FDA reviewed the website www.ketacynpharma.com (establishment identifier 3043544178) on February 26, 2026. The agency found ketamine products offered for sale, including "Ketamine Solution for Injection (500 mg/10 mL)" and "Ketamine Gummies," that have no FDA-approved application. FDA also said the site offers these prescription drugs without requiring a prescription and without adequate directions for use.
What FDA found
The company sells ketamine drug products that FDA has never approved.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))The product labeling does not give adequate directions for use, and the products are not exempt because they are unapproved.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1)); 21 CFR 201.115(a)The company offers prescription drugs without requiring a prescription from a licensed practitioner.
FD&C Act section 503(b)(1) (21 U.S.C. 353(b)(1))Offering these drugs this way puts misbranded drugs into interstate commerce.
FD&C Act sections 301(a) and 301(k) (21 U.S.C. 331(a), 331(k))
What FDA wants
FDA asks the company to stop offering unapproved and misbranded drugs for sale to U.S. consumers and to send a written response with corrective steps and supporting documents to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov, citing reference number MARCS-CMS 725153.
Who should pay attention
- online pharmacies and telehealth sellers of ketamine products
- compounders and manufacturers making ketamine injection or edible forms
- clinics and brands that buy or resell ketamine from third parties
This is a summary. Read the original letter on fda.gov.